Ulcerative Paraneoplastic Dermatomyositis in the Setting of Positive Transcriptional Intermediary Factor 1-γ Antibody

REFERENCES

1. 1.↵
   1. Masiak A,
   2. Kulczycka J,
   3. Czuszyńska Z,
   4. Zdrojewski Z.

   Clinical characteristics of patients with anti-TIF1-γ antibodies. Reumatologia 2016;54:14-8.

   OpenUrl
2. 2.↵
   1. Oldroyd A,
   2. Sergeant JC,
   3. New P,
   4. McHugh NJ,
   5. Betteridge Z,
   6. Lamb JA, et al.

   The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody–positive dermatomyositis. Rheumatology 2019;58:650-5.

   OpenUrl
3. 3.↵
   1. Hall JC,
   2. Casciola-Rosen L,
   3. Samedy LA,
   4. Werner J,
   5. Owoyemi K,
   6. Danoff SK, et al.

   Anti-MDA 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res 2013; 65:1307-15.

   OpenUrlCrossRef
4. 4.↵
   1. Moghadam-Kia S,
   2. Oddis CV,
   3. Sato S,
   4. Kuwana M,
   5. Aggarwal R.

   Anti–melanoma differentiation–associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res 2016;68:689-94.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Betteridge Z,
   2. McHugh N.

   Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 2016;280:8-23.

   OpenUrlCrossRefPubMed